Radiosensitization of HSF-1 Knockdown Lung Cancer Cells by Low Concentrations of Hsp90 Inhibitor NVP-AUY922

被引:19
|
作者
Kuehnel, Annett [1 ,2 ]
Schilling, Daniela [1 ,2 ]
Combs, Stephanie E. [1 ,2 ,3 ]
Haller, Bernhard [4 ]
Schwab, Melissa [5 ]
Multhoff, Gabriele [1 ,5 ]
机构
[1] Tech Univ Munich, Klinikum Rechts Isar, Dept Radiat Oncol, Ismaninger Str 22, D-81675 Munich, Germany
[2] Helmholtz Zentrum Munchen, DRS, IRM, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany
[3] DKTK, Partner Site Munich, D-81675 Munich, Germany
[4] Tech Univ Munich, Klinikum Rechts Isar, Inst Med Informat Stat & Epidemiol, Ismaningerstr 21, D-81675 Munich, Germany
[5] Tech Univ Munchen TranslaTUM, Klinikum Rechts Isar, Ctr Translat Canc Res, Einsteinstr 25, D-81675 Munich, Germany
关键词
heat shock factor (HSF-1) knockdown; heat shock proteins 70 and 27; radiosensitization; Hsp90 inhibitor NVP-AUY922; homologous recombination (HR); HEAT-SHOCK PROTEINS; SENSITIZING TUMOR-CELLS; DNA-DAMAGE RESPONSE; IN-VITRO; CHAPERONE INHIBITORS; RADIATION RESPONSE; FACTOR-1; 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN; GELDANAMYCIN; EXPRESSION;
D O I
10.3390/cells8101166
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The inhibition of heat shock protein 90 (Hsp90) a molecular chaperone for multiple oncogenic client proteins is considered as a promising approach to overcome radioresistance. Since most Hsp90 inhibitors activate HSF-1 that induces the transcription of cytoprotective and tumor-promoting stress proteins such as Hsp70 and Hsp27, a combined approach consisting of HSF-1 knockdown (k.d.) and Hsp90 inhibition was investigated. A specific HSF-1 k.d. was achieved in H1339 lung cancer cells using RNAi-Ready pSIRENRetroQ vectors with puromycin resistance. The Hsp90 inhibitor NVP-AUY922 was evaluated at low concentrations-ranging from 1-10 nM-in control and HSF-1 k.d. cells. Protein expression (i.e., Hsp27/Hsp70, HSF-1, pHSF-1, Akt, beta-actin) and transcriptional activity was assessed by western blot analysis and luciferase assays and radiosensitivity was measured by proliferation, apoptosis (Annexin V, active caspase 3), clonogenic cell survival, alkaline comet, gamma H2AX, 53BP1, and Rad51 foci assays. The k.d. of HSF-1 resulted in a significant reduction of basal and NVP-AUY922-induced Hsp70/Hsp27 expression levels. A combined approach consisting of HSF-1 k.d. and low concentrations of the Hsp90 inhibitor NVP-AUY922 reduces the Hsp90 client protein Akt and potentiates radiosensitization, which involves an impaired homologous recombination mediated by Rad51. Our findings are key for clinical applications of Hsp90 inhibitors with respect to adverse hepatotoxic effects.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells
    Alexandra Canonici
    Zulfiqar Qadir
    Neil T. Conlon
    Denis M. Collins
    Neil A. O’Brien
    Naomi Walsh
    Alex J. Eustace
    Norma O’Donovan
    John Crown
    Investigational New Drugs, 2018, 36 : 581 - 589
  • [32] Signaling profile and anti-tumor activity of the novel HSP90 inhibitor NVP-AUY922 in multiple myeloma
    Stuehmer, Thorsten
    Zoellinger, Angela
    Siegmund, Daniela
    Chatterjee, Manik
    Grella, Evelyn
    Knop, Stefan
    Kortuem, Martin
    Unzicker, Christian
    Jensen, Michael R.
    Quadt, Cornelia
    Chene, Patrick
    Schoepfer, Joseph
    Garcia-Echeverria, Carlos
    Einsele, Herrmann
    Wajant, Harald
    Bargou, Ralf C.
    BLOOD, 2007, 110 (11) : 270B - 271B
  • [33] HSP90 Inhibitor, NVP-AUY922, Improves Myelination in Vitro and Supports the Maintenance of Myelinated Axons in Neuropathic Mice
    Chittoor-Vinod, Vinita G.
    Bazick, Hannah
    Todd, Adrian G.
    Falk, Darin
    Morelli, Kathryn H.
    Burgess, Robert W.
    Foster, Thomas C.
    Notterpek, Lucia
    ACS CHEMICAL NEUROSCIENCE, 2019, 10 (06): : 2890 - 2902
  • [34] The novel HSP90 inhibitor NVP-AUY922 shows synergistic anti-leukemic activity with cytarabine in vivo
    Wendel, Torunn
    Zhen, Yan
    Suo, Zenhe
    Bruheim, Skjalg
    Wiedlocha, Antoni
    EXPERIMENTAL CELL RESEARCH, 2016, 340 (02) : 220 - 226
  • [35] Preclinical evaluation of the novel, potent diarylisoxazole resorcinol HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastomas
    Gaspar, Nathalie
    Sharp, Swee
    Eccles, Sue
    Valenti, Melanie
    Patterson, Lisa
    Gowan, Sharon
    Jones, Chris
    Vassal, Gilles
    Pearson, Andrew
    Workman, Paul
    NEURO-ONCOLOGY, 2008, 10 (03) : 513 - 513
  • [36] Biologic effects of NVP-AUY922, a novel small molecule inhibitor of HSP90 in human colon and gastric cancer cell lines
    Wainberg, Zev
    Anghel, Adrian
    Desai, Amrita
    Adhani, Shahriar
    Safran, Brent
    Hecht, J.
    Jensen, Michael
    Quadt, Cornelia
    Slamon, Dennis
    Finn, Richard
    CANCER RESEARCH, 2009, 69
  • [37] The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib
    Park, Kang-Seo
    Oh, Bora
    Lee, Mi-Hee
    Nam, Ky-Youb
    Jin, Hae Ran
    Yang, Hannah
    Choi, Junyoung
    Kim, Sang -We
    Lee, Dae Ho
    CANCER LETTERS, 2016, 372 (01) : 75 - 81
  • [38] Hsp90 inhibitor (NVP-AUY922) enhances anti-cancer effect of Bcl-2 inhibitor (ABT-737) in small cell lung cancer
    Yang, Hannah
    Park, Kang-Seo
    Choi, Junyoung
    Kim, Sang-We Kim
    Lee, Dae Ho
    CANCER RESEARCH, 2017, 77
  • [39] 89Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922
    Nagengast, Wouter B.
    de Korte, Maarten A.
    Munnink, Thijs H. Oude
    Timmer-Bosscha, Hetty
    den Dunnen, Wifred F.
    Hollema, Harry
    de Jong, Johan R.
    Jensen, Michael R.
    Quadt, Cornelia
    Garcia-Echeverria, Carlos
    van Dongen, Guus A. M. S.
    Lub-de Hooge, Marjolijn N.
    Schroder, Carolien P.
    de Vries, Elisabeth G. E.
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (05) : 761 - 767
  • [40] Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake
    Monazzam, Azita
    Razifar, Pasha
    Ide, Susan
    Jensen, Michael Rugaard
    Josephsson, Raymond
    Blomqvist, Carl
    Langstroemg, Bengt
    Bergstroem, Mats
    NUCLEAR MEDICINE AND BIOLOGY, 2009, 36 (03) : 335 - 342